The following adverse effects have been reported in studies with<unk> : Very common: Headache predominates (up to 30%) necessitating withdrawal of 2 to 3% of patients, but the incidence reduces rapidly as treatment continues. Common: Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with<unk>  modified-release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%) Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment. Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. In general, these symptoms disappear during long-term treatment. Other reactions that have been reported with<unk> -modified release tablets include tachycardia, vomiting, diarrhoea, vertigo, and heartburn.
Isosorbide mononitrate
Isosorbide dinitrate
Sodium nitroprusside
Minoxidil
Balsalazide
Hydralazine
Telmisartan
Captopril